rs184660829 — DENND2C

Rare intronic variant near a DENND2C splice site associated with an 8-fold increase in type 2 diabetes risk in carriers of European ancestry.

See your personal result for DENND2C

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

DENND2C rs184660829 — A Rare Intronic Signal With a Large Diabetes Footprint

Most genetic risk variants for type 2 diabetes (T2D) are common, each nudging risk upward by a small amount. rs184660829 works differently: it is vanishingly rare — found in fewer than 1 in 2,500 people of European ancestry and essentially absent elsewhere — but carries one of the largest odds ratios for T2D yet identified in a genome-wide study. Carriers of the C allele face roughly 8 times the population risk of developing type 2 diabetes compared to the vast majority of people who carry two copies of the common T allele.

The Gene and Its Mechanism

DENND2C (DENN domain containing 2C11 DENN domain containing 2C
a family of guanine nucleotide exchange factors (GEFs) that activate Rab GTPases) is a protein that controls vesicle trafficking — the cellular process by which membrane-bound packages of molecules are routed to their correct destinations. Rab GTPases are the molecular switches that direct this traffic, and DENND2C turns them on by catalyzing the exchange of GDP for GTP. Disruption of this switch-throwing activity has consequences for any tissue that depends on precise vesicle delivery, including the pancreatic beta cells that must release insulin granules on demand in response to rising blood glucose.

The rs184660829 variant sits 84 nucleotides upstream of a splice site in intron 11 of DENND2C (GRCh38: chr1:114,602,278, coding notation c.1668-84A>G on the minus strand). It is not in the protein-coding sequence and produces no amino acid change; instead, it may subtly alter splicing efficiency or local chromatin state in a tissue-specific way. The variant lies within a genomic region that, per islet epigenome maps used in the Mahajan 2018 fine-mapping study, shows regulatory chromatin marks in pancreatic islets — consistent with a gene-regulatory rather than structural mechanism.

The Evidence

Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.22 Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.
Mahajan A et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018 Nov;50(11):1505-1513. rs184660829-C emerged as one of the rare index variants (MAF <5%) with an estimated allelic odds ratio exceeding 2-fold — specifically OR=8.05 (95% CI 3.86–16.8, p=3×10⁻⁸), meeting genome-wide significance. The variant's risk allele frequency is approximately 2×10⁻⁴ globally, meaning the association was detected despite very few carriers, which underscores the strength of the biological signal.

Because the variant is intronic and its mechanism is not fully characterized, the evidence level is classified as moderate: the GWAS signal is genome-wide significant and the locus is biologically plausible, but functional validation in human islets and replication in non-European populations have not been published. The study was conducted exclusively in European-ancestry samples, and the C allele has not been observed at appreciable frequency in African, East Asian, South Asian, or Latino populations in gnomAD or ALFA population databases.

Practical Actions

Carriers of the C allele (TC genotype) should understand that their genetic background places them at substantially elevated T2D risk relative to the general population. The most evidence-backed strategies for individuals with high genetic T2D risk target fasting glucose monitoring and dietary carbohydrate quality — interventions with documented efficacy specifically in genetically at-risk individuals. Because the DENND2C locus likely affects beta cell vesicle function rather than insulin resistance in peripheral tissues, the primary vulnerability is in insulin secretion capacity, making monitoring of beta cell reserve (via fasting insulin and HOMA-B calculations) particularly informative.

Interactions

DENND2C rs184660829 is a recently discovered rare-variant signal and no published compound interactions with other T2D loci have been characterized. However, high-T2D-risk individuals carrying this allele who also carry common risk variants in TCF7L2 (rs7903146) or MTNR1B (rs10830963) may experience additive risk burden on a polygenic basis. These interactions are theoretical and have not been formally studied in the context of rs184660829.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-carrier Normal

Common genotype — standard type 2 diabetes risk

You carry two copies of the common T allele at rs184660829 in the DENND2C gene. This is the genotype found in more than 99.9% of people. Your DENND2C-related contribution to type 2 diabetes risk is unremarkable; any T2D risk you carry comes from other genetic and lifestyle factors, not this variant.

CT Risk Carrier High Risk

Rare C allele carrier — approximately 8-fold elevated T2D risk

The rs184660829-C allele sits 84 bp upstream of an intron 11 splice site in DENND2C, a guanine nucleotide exchange factor that activates Rab GTPases involved in vesicle trafficking. DENND2C has been shown to regulate actin-dependent membrane dynamics (Koyanagi et al. 2024, PMID 39519032) and RHOA signaling (Gayle et al. 2015, PMID 25866159). Pancreatic beta cells are exquisitely dependent on regulated vesicle exocytosis for insulin granule release; disruption of the Rab GTPase axis in this context could impair stimulus-secretion coupling.

The Mahajan 2018 fine-mapping study integrated islet-specific epigenome data with genetic association signals — suggesting the DENND2C locus has regulatory activity specifically in islet tissue. The variant is extremely rare (MAF ~0.02% in Europeans, absent in other ancestries) and the GWAS association rests on a relatively small absolute number of carriers, so the confidence interval is wide. The evidence level is moderate: genome-wide significant, biologically plausible, but not yet functionally validated at the variant level.

CC Homozygous High Risk

Homozygous for rare risk allele — very high T2D risk, effectively unobserved in population data

Because CC homozygosity for rs184660829 is essentially unobserved in gnomAD (v4) and ALFA population databases, there is no direct human evidence on the CC phenotype. Extrapolating from an additive log-linear model, two C alleles would correspond to an OR of approximately 8.05² ≈ 65, though this must be treated as a theoretical estimate. The immediate clinical priority is verification that the genotype call is correct (sequencing artefacts are more likely for ultra-rare homozygotes than for heterozygotes) and prompt metabolic assessment.